Story perspectives

Sanofi, Regeneron Expand Antibody Deal Up to $8 Billion

By Drooid · Oct 1, 2026, 10:13 PM UTC · How we work

Summary

Story summary

Sanofi and Regeneron expanded their antibody partnership in a deal up to $8 billion.
Sanofi will pay $1 billion upfront and could receive up to $7 billion in milestones.
Regeneron will lead R&D while Sanofi handles global sales and splits costs and profits equally.
Analysts said the deal is positive but warned the drugs are early-stage and may not replace Dupixent.

History

Historical Context

Humira, the first fully human monoclonal antibody, received FDA approval in 2002 after a 1993 BASF-Cambridge Antibody Technology collaboration, and became AbbVie’s flagship product following Abbott’s 2013 split. Its $20.4 billion global sales in 2020 sparked a wave of large-pharma-biotech partnerships that now shape antibody pipelines and pricing debates throughout the industry.

1 of 2

Story summary

Sanofi and Regeneron expanded their antibody partnership in a deal up to $8 billion.
Sanofi will pay $1 billion upfront and could receive up to $7 billion in milestones.
Regeneron will lead R&D while Sanofi handles global sales and splits costs and profits equally.
Analysts said the deal is positive but warned the drugs are early-stage and may not replace Dupixent.

1 / 2